<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823352</url>
  </required_header>
  <id_info>
    <org_study_id>GHAML-2-001</org_study_id>
    <nct_id>NCT03823352</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients</brief_title>
  <official_title>Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golden Biotechnology Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule,&#xD;
      100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The given pilot clinical trial of a medicinal product for medical use, is held to evaluate&#xD;
      preliminary efficacy and safety/tolerability profiles of antroquinonol in adult patients with&#xD;
      relapsed AML or at initial diagnosis when no intensive treatment is possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete blood count measurements according International Working Group (IWG) response criteria</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluation of preliminary efficacy profile of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants alive at 4weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>patients' situation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants alive at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>patients' situation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Antroquinonol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antroquinonol</intervention_name>
    <description>Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.</description>
    <arm_group_label>Antroquinonol</arm_group_label>
    <other_name>Hocena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of relapsed AML after at least 1 chemotherapy regimen or at initial&#xD;
             diagnosis when no intensive treatment possible (based on standard criteria).&#xD;
&#xD;
          2. Men and women 18 to 70 years of age.&#xD;
&#xD;
          3. ECOG performance status = 0 or 1.&#xD;
&#xD;
          4. Ability to comply with the study requirements and give written informed consent.&#xD;
&#xD;
          5. Expected survival more than 3 months.&#xD;
&#xD;
          6. Patients with preserved reproductive potential agree to use, with their partner,&#xD;
             adequate contraception throughout the study and for 30 days thereafter (contraceptive&#xD;
             methods with reliability greater than 90%: cervical caps with spermicide, diaphragms&#xD;
             with spermicide, condoms with intravaginal spermicide, non-hormonal intrauterine&#xD;
             devices), or true sexual abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia (APL).&#xD;
&#xD;
          2. Hemoglobin ≤ 7g/dL or platelet ≤ 50,000.&#xD;
&#xD;
          3. Abnormal liver and renal function:&#xD;
&#xD;
               -  Total bilirubin &gt; 2 mg/dL;&#xD;
&#xD;
               -  AST and ALT &gt; 2.5 × ULN;&#xD;
&#xD;
               -  Creatinine &gt; 1.5 × ULN, OR creatinine clearance &lt; 50 mL/min/1.73m2.&#xD;
&#xD;
          4. The subject has not recovered to grade ≤ 1 adverse events due to investigational or&#xD;
             chemotherapeutic drugs or stem cell transplantation which were administered &gt; 4 weeks&#xD;
             prior to study enrollment.&#xD;
&#xD;
          5. Patient who has had in the past 3 years any previous or concomitant malignancy EXCEPT&#xD;
             adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of&#xD;
             the cervix or bladder, in situ ductal carcinoma of the breast.&#xD;
&#xD;
          6. Subjects with any serious active infection (i.e., requiring an intravenous antibiotic,&#xD;
             antifungal, or antiviral agent).&#xD;
&#xD;
          7. Subjects with known human immunodeficiency virus, active hepatitis B or C.&#xD;
&#xD;
          8. Subjects who have any other life-threatening illness or organ system dysfunction,&#xD;
             which in the opinion of the Investigator, would either compromise subject safety or&#xD;
             interfere with the evaluation of the safety of the study drug.&#xD;
&#xD;
          9. Known or suspected substance abuse or alcohol abuse.&#xD;
&#xD;
         10. Patients with history of seizure disorders or central nervous system leukemia.&#xD;
&#xD;
         11. Patients with uncontrolled, intercurrent illness including, but not limited to,&#xD;
             symptomatic neurological illness; active, uncontrolled, systemic infection considered&#xD;
             opportunistic, life-threatening, or clinically significant at the time of treatment;&#xD;
             symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia;&#xD;
             significant pulmonary disease or hypoxia; or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
         12. Inability to swallow oral medications or a recent acute gastrointestinal disorder with&#xD;
             diarrhea e.g., Crohn's disease, malabsorption, or CTCAE Grade &gt; 2 diarrhea of any&#xD;
             etiology at baseline.&#xD;
&#xD;
         13. Prior major surgery or trauma within 28 days prior to first dose of study drug.&#xD;
&#xD;
         14. A positive urine pregnancy test (strip) for female patients of childbearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. S.P.Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Hospital</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

